Kestra Medical Technologies, Ltd. (KMTS) Q1 2027 Earnings Call Transcript

SA Transcripts 162.21K Followers Follow Kestra Medical Technologies, Ltd. ( KMTS ) Q1 2027 Earnings Call September 14, 2026 4:30 PM EDT Company Participants Neil Bhalodkar - Vice President of Investor Relations Brian Webster - Founder, President, CEO & Director Vaseem Mahboob - Chief Financial Officer Conference Call Participants Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Matthew O'Brien - Piper Sandler & Co., Research Division Michael Polark - Wolfe Research, LLC Marie Thibault - BTIG, LLC, Research Division Frederick Wise - Stifel, Nicolaus & Company, Incorporated, Research Division Stephanie Piazzola - BofA Securities, Research Division Suraj Kalia - Oppenheimer & Co. Inc., Research Division Presentation Operator Good afternoon, and welcome to Kestra Medical Technologies First Quarter Fiscal 2027 Earnings Conference Call. This conference call is being recorded for replay purposes. [Operator Instructions] I would now like to turn the call over to Neil Bhalodkar, Vice President of Investor Relations for introductory comments. Neil Bhalodkar Vice President of Investor Relations Thank you, [ Latif. ] Good afternoon. Thank you for joining Kestra's First Quarter Fiscal 2027 Earnings Call. With me today are Brian Webster, President and Chief Executive Officer; and Vaseem Mahboob, Chief Financial Officer. This call includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements made on this call that do not relate to matters of historical fact should be considered forward-looking statements. These statements are based on Kestra's current expectations, forecasts and assumptions, which are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Actual outcomes and results could differ materially from any results, performance or achievements expressed or implied by the forward-looking statements due to various factors. Please review Kestra's most recent filings with the SEC, particularly the risk factors described in our Form 10-K for additional information. Any forward-looking statements provided during this call, including projections of future performance, are